Cellectis SA (CLLS) Earnings Date & Reports

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CLLS is expected to report earnings to rise 46.67% to -26 cents per share on July 30

Cellectis SA CLLS Stock Earnings Reports

Q2'26

Est.

$-0.26

Q1'26

Beat

by $0.08

Q4'25

Beat

by $0.03

Q3'25

Beat

by $0.24

Q2'25

Missed

by $0.02

The last earnings report on May 11 showed earnings per share of -18 cents, beating the estimate of -25 cents. With 100.00 shares outstanding, the current market capitalization sits at 312.83M.

View a ticker or compare two or three

Compare

CLLS

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for CLLS